Call to Federal Government for equitable access to DFMO

DFMO (eflornithine) was approved in December 2023 by FDA for treatment of high-risk neuroblastoma as a maintenance therapy to reduce the risk of relapse Read more

You Doubled Your Impact!

In March, Neuroblastoma Australia joined Beyond Bank's 2024 Double Donation campaign. For 48 hours, Beyond Bank doubled donations up to $10,000. Read more

Fundraising on Instagram

Did you know you can now fundraise on Instagram? Find out more, including a step-by-step guide to getting started. Read more

Jean-Christophe Novelli Announced as Neuroblastoma Australia Ambassador

We're thrilled to welcome award winning chef and restaurateur, Jean-Christophe Novelli, as a Neuroblastoma Australia ambassador. Read more

Senate Inquiry into Equitable Diagnosis and Treatment Access

On Wednesday Jan 31, Neuroblastoma Australia CEO Lucy Jones, addressed the Senate panel and outlined the changes that are desperately needed to improve the lives of children diagnosed with neuroblastoma. Read more